Stronger MS Medicines Cut Relapse-Related Disability

Credibility

Interest

Key Takeaway

Starting a high-efficacy MS therapy early lowered the chance of disability caused by relapses, but it did not change the risk of gradual worsening that happens without relapses.

What They Found

Researchers followed 2,563 people with relapsing-onset MS who had not used disease-modifying therapy before. They compared two first treatment types: platform therapies (standard, often gentler medicines) and high-efficacy therapies (stronger medicines). People who began high-efficacy therapy had fewer relapse-associated disability events — think of relapses as sudden storms that damage the nervous system, and these stronger medicines reduced storm damage. However, the chance of slow, steady worsening that happens without clear relapses (like a slow leak that adds up over time) was about the same regardless of which treatment was started. Overall disability scores rose faster for people who began with platform therapy, and the stronger-treatment group reached fewer disability milestones during follow-up.

Who Should Care and Why

People with relapsing-onset MS and their caregivers should care because the choice of first treatment may affect how much disability comes from relapses — similar to picking a better umbrella to avoid storm damage. Patients prone to frequent or severe relapses may benefit most from high-efficacy therapies to prevent sudden loss of function. Caregivers and family can use this information when talking with doctors about starting strong treatment early, especially if relapses have caused noticeable setbacks before. Clinicians should note that while stronger drugs reduce relapse-related harm, they don’t seem to stop the slow, relapse-independent decline, so other strategies are still needed. This may change daily planning: reducing relapses can mean fewer sudden hospital visits and more predictable day-to-day abilities.

Important Considerations

This study is observational, not a randomized trial, so treatment choices may reflect other factors (for example, people with worse symptoms might have been more likely to get stronger drugs), which can affect results. Follow-up stopped when people switched or stopped treatment, so we don’t know long-term effects after changing medicines. The findings show differences in relapse-related disability but do not prove high-efficacy therapies prevent the slow, gradual decline, so talk with your care team about risks, benefits, and monitoring.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates MS Progression Clinical Trials

Article Topics:

Disease-modifying therapyExpanded disability status scaleMultiple sclerosisProgression independent of relapse activityRelapse-associated worsening

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News